首页> 美国卫生研究院文献>Journal of the Royal Society Interface >Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds
【2h】

Structural insights into human heme oxygenase-1 inhibition by potent and selective azole-based compounds

机译:有效和选择性的基于唑的化合物对人血红素加氧酶-1抑制的结构见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of heme oxygenase (HO) inhibitors, especially those that are isozyme-selective, promises powerful pharmacological tools to elucidate the regulatory characteristics of the HO system. It is already known that HO has cytoprotective properties and may play a role in several disease states, making it an enticing therapeutic target. Traditionally, the metalloporphyrins have been used as competitive HO inhibitors owing to their structural similarity with the substrate, heme. However, given heme's important role in several other proteins (e.g. cytochromes P450, nitric oxide synthase), non-selectivity is an unfortunate side-effect. Reports that azalanstat and other non-porphyrin molecules inhibited HO led to a multi-faceted effort to develop novel compounds as potent, selective inhibitors of HO. This resulted in the creation of non-competitive inhibitors with selectivity for HO, including a subset with isozyme selectivity for HO-1. Using X-ray crystallography, the structures of several complexes of HO-1 with novel inhibitors have been elucidated, which provided insightful information regarding the salient features required for inhibitor binding. This included the structural basis for non-competitive inhibition, flexibility and adaptability of the inhibitor binding pocket, and multiple, potential interaction subsites, all of which can be exploited in future drug-design strategies.
机译:血红素加氧酶(HO)抑制剂的发展,特别是那些对同工酶具有选择性的抑制剂,有望成为有力的药理学工具,以阐明HO系统的调节特性。众所周知,HO具有细胞保护特性,并可能在几种疾病状态中起作用,使其成为诱人的治疗靶标。传统上,金属卟啉由于与底物血红素的结构相似性而被用作竞争性HO抑制剂。但是,考虑到血红素在其他几种蛋白质(例如细胞色素P450,一氧化氮合酶)中的重要作用,非选择性是一种不幸的副作用。有报道称,氮杂兰司他和其他非卟啉分子抑制HO导致了多方面的努力,以开发出新型化合物作为HO的有效选择性抑制剂。这导致产生对HO具有选择性的非竞争性抑制剂,包括对HO-1具有同工酶选择性的子集。使用X射线晶体学,已经阐明了HO-1与新型抑制剂的几种配合物的结构,这为抑制剂结合所需的显着特征提供了有见地的信息。这包括非竞争性抑制的结构基础,抑制剂结合口袋的灵活性和适应性,以及多个潜在的相互作用亚位点,所有这些都可以在未来的药物设计策略中加以利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号